Technological advancements in cancer treatments such as Chemotherapy and rising investment in cancer care are reducing the number of cancer deaths worldwide. According to the Cancer Journal for Clinicians 2016 study, the number of cancer survivors continues to grow in the U.S. due to increasing number of new cancer diagnoses resulting from a growing and aging population. As per the same report, over 15.5 million Americans with a history of cancer were alive on January 1, 2016 and this number is projected to reach 20.3 million by January 1, 2026.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2231

Chemotherapy is most often administrated via a vein (intravenously) using devices such as catheter and ports. Long-term central venous access devices are essential for the management of cancer patients, as they minimize the discomfort of frequent venipuncture and cannulation. A catheter reduce the number of times to insert a needle in patient vein. According to the WHO 2017 report, in most upper and middle income countries, the chemotherapy dosage for some treatments and for patients with metastatic diseases is done using implantable central venous catheters or peripherally inserted central catheters (PICC).

Manufacturers in the chemotherapy devices market are focused on technological advancements in devices. For instance, in May 2018, Advanced Chemotherapy Technologies announced development of an implant, about the size of a large coin for direct delivery of chemo agents into the pancreas. In 2017, RenovoRx received FDA approval for RenovoCath dual-balloon infusion catheter to include the delivery of chemotherapeutics.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2231

Increasing incidences of different cancers worldwide is the major factor driving chemotherapy devices market growth. According to the World Health Organization (WHO), 2017, nearly 1 in 6 deaths occur due to cancer globally and around 70% of deaths from cancer occur in low- and middle-income economies. According to Breast Cancer Organization, in 2017, approximately 252,710 new cases of breast cancer were identified in the U.S., of which 63,410 cases were of non-invasive breast cancer.

Moreover, increasing government and private funding coupled with rising disposable income is also projected to drive chemotherapy devices market growth. According to the National Cancer Institute 2016 report, an estimated national expenditures for cancer care in the U.S. in 2017, were US$ 147.3 billion. Costs are likely to increase over the forecast period, as the population ages and cancer prevalence increases. However, not all chemotherapy patient requires a venous access device. For some chemotherapy treatment plans, the inconvenience of implanting and accessing a VAD can outweigh the benefits.

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/2231

Key players operating in the global chemotherapy devices market include Advanced Chemotherapy Technologies, Baxter International, Becton, Dickinson, B. Braun, Fresenius Kabi, Halyard Health, ICU Medical, Moog Inc., Micrel Medical, Smiths Group, Terumo Corporation, and Zyno Medical

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]